Poor
Needs Revision
Patient Risk:
Moderate
Summary
Several core claims are not supported by the provided FDA label excerpts (notably indication age cutoff and multiple mechanism/side-effect descriptions). Multiple dosing/administration safety instructions included in the excerpts are omitted. Some safety-related warnings are only partially aligned at best (e.g., psychiatric/neurological adverse reactions are mentioned in label, but the specific side-effect list and monitoring instruction are not fully supported by the provided text).
Category Scores
Accurate Statements
Briviact has the active ingredient brivaracetam.
Drug/active ingredient provided by user matches label context (brivaracetam named in contraindications excerpt: 'Hypersensitivity to brivaracetam').
Briviact is an antiepileptic drug.
Label excerpt uses 'Antiepileptic drugs (AEDs), including BRIVIACT' (Section 5.1).
Commonly reported side effects of Briviact include drowsiness.
Section 5.2: 'BRIVIACT causes somnolence, fatigue, dizziness, and disturbance in coordination.' (somnolence aligns with drowsiness).
Commonly reported side effects of Briviact include dizziness.
Section 5.2: '... dizziness ...' and Section 6.1: 'dizziness (12%).'
Commonly reported side effects of Briviact include fatigue.
Section 5.2: '... fatigue ...' and Section 6.1: 'fatigue (9%).'
Unsupported Statements
Briviact 100 mg oral tablet is prescribed for the treatment of partial-onset seizures in patients 4 years of age and older with epilepsy.
Provided label excerpt states indication for 'patients 1 month of age and older' (Section 1). The '4 years and older' restriction is not supported.
Briviact 100 mg oral tablet is taken by mouth.
The provided excerpts include administration instructions but do not explicitly state 'taken by mouth' for the tablet; 'tablets... may be taken with or without food' (Section 2.2) implies oral use, but the exact phrasing is not directly supported by the provided text.
Briviact works by selectively binding to synaptic vesicle protein 2A (SV2A) in the brain.
No mechanism of action (SV2A binding) is provided in the supplied label excerpts.
Binding to SV2A is believed to modulate the release of neurotransmitters.
Not present in supplied label excerpts.
Modulating the release of neurotransmitters reduces abnormal electrical activity that leads to seizures.
Not present in supplied label excerpts.
Commonly reported side effects of Briviact include behavioral changes such as aggression.
The label excerpts state 'BRIVIACT causes psychiatric adverse reactions' (Section 5.3) but do not specify aggression or behavioral change types (Section 6.1 excerpt lists only somnolence/sedation, dizziness, fatigue, nausea/vomiting).
Commonly reported side effects of Briviact include mood changes.
Section 5.3 indicates psychiatric adverse reactions but the provided excerpts do not specifically list 'mood changes' as commonly reported.
Patients and healthcare providers should monitor for drowsiness, dizziness, fatigue, and behavioral changes and any other adverse reactions.
Label excerpts list adverse reactions and precautions, but the specific instruction to monitor for the listed symptoms (and 'any other adverse reactions') is not explicitly stated in the provided excerpts.
Briviact is marketed by UCB Pharma.
No marketing company information is included in the provided label excerpts.
Clinical trials have demonstrated Briviact's effectiveness in reducing the frequency of partial-onset seizures.
Clinical studies excerpt states effectiveness was established in placebo-controlled studies (Section 14) but does not explicitly state 'reducing frequency' in the provided excerpt.
Clinical trials typically evaluate the drug's ability to decrease seizure burden compared to placebo in patients with epilepsy.
The provided excerpt mentions 'fixed-dose, randomized, double-blind, placebo-controlled' studies (Section 14) but does not mention 'seizure burden' terminology.
Briviact has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of epilepsy in specific patient populations.
The provided excerpts confirm FDA labeling content but do not explicitly state approval by FDA or use of 'epilepsy' wording beyond the partial-onset seizure indication; also 'specific patient populations' is not explicitly detailed in provided excerpts.
Contradictions
Important Omissions
Indication age range: label excerpt specifies partial-onset seizures in patients 1 month of age and older; AI claimed 4 years and older (material discrepancy already captured under unsupported).
Importance:
High
Tablets administration instructions: tablets should be swallowed whole with liquid; should not be chewed or crushed; may be taken with or without food (Section 2.2).
Importance:
Moderate
Dose adjustment guidance: dosage should be adjusted based on clinical response and tolerability (Section 2.1).
Importance:
Moderate
Discontinuation warning: avoid abrupt withdrawal to minimize risk of increased seizure frequency and status epilepticus (Section 2.4 / 5.6).
Importance:
High
Key warnings/precautions beyond the listed symptoms: suicidal thoughts/behavior risk (Section 5.1), hypersensitivity with bronchospasm and angioedema (Section 5.4), and serious dermatologic reactions including SJS/TEN (Section 5.5).
Importance:
High
More complete adverse reaction listing: common adverse reactions at ≥5% include somnolence/sedation, dizziness, fatigue, and nausea/vomiting symptoms (Section 6.1); AI did not mention nausea/vomiting or sedation distinction.
Importance:
Moderate
Drug interaction with rifampin requiring up to doubling the brivaracetam dose (Section 7.1) and levetiracetam co-administration provides no added benefit (Section 7.4) are not discussed (omission may be material for interaction questions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Material discrepancy in age indication ('4 years and older' vs label '1 month and older') plus omission of key warnings (suicidal behavior, hypersensitivity, serious dermatologic reactions, and abrupt withdrawal risk) could lead to incomplete or misleading information relative to label guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Indication age cutoff is incorrect vs label; multiple mechanism and side-effect claims are not supported by provided label excerpts, and several key warnings/administration/discontinuation instructions are omitted.
Suggested Improvement
Revise indication to 'patients 1 month of age and older' per Section 1; restrict adverse reaction listings to what is supported (somnolence/sedation, dizziness, fatigue, nausea/vomiting; and generally 'psychiatric adverse reactions' without specific aggression/mood terms); remove or label as not in provided labeling any SV2A mechanism details; include label-required administration and discontinuation cautions (swallow whole, avoid abrupt withdrawal) and key warnings (suicidal thoughts/behavior, hypersensitivity/bronchospasm/angioedema, SJS/TEN) as applicable.